Journal
PHARMACEUTICALS
Volume 15, Issue 4, Pages -Publisher
MDPI
DOI: 10.3390/ph15040463
Keywords
beta-lactams; beta-lactamase inhibitors; cefiderocol; pharmacokinetics; pharmacodynamics
Categories
Ask authors/readers for more resources
Bacterial resistance mechanisms are continuously and rapidly evolving, especially for Gram-negative bacteria. The strategy of developing new beta-lactam/beta-lactamase inhibitors (BLs/BLIs) combinations has been successful, and data on several compounds are becoming available. Cefiderocol, with its unique mechanism of action, warrants separate discussion.
Bacterial resistance mechanisms are continuously and rapidly evolving. This is particularly true for Gram-negative bacteria. Over the last decade, the strategy to develop new beta-lactam/beta-lactamase inhibitors (BLs/BLIs) combinations has paid off and results from phase 3 and real-world studies are becoming available for several compounds. Cefiderocol warrants a separate discussion for its peculiar mechanism of action. Considering the complexity of summarizing and integrating the emerging literature data of clinical outcomes, microbiological mechanisms, and pharmacokinetic/pharmacodynamic properties of the new BL/BLI and cefiderocol, we aimed to provide an overview of data on the following compounds: aztreonam/avibactam, cefepime/enmetazobactam, cefepime/taniborbactam, cefepime/zidebactam, cefiderocol, ceftaroline/avibactam, ceftolozane/tazobactam, ceftazidime/avibactam, imipenem/relebactam, meropenem/nacubactam and meropenem/vaborbactam. Each compound is described in a dedicated section by experts in infectious diseases, microbiology, and pharmacology, with tables providing at-a-glance information.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available